Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Other financing activities (2022 - 2024)

Tandem Diabetes Care (TNDM) has disclosed Other financing activities for 4 consecutive years, with $183000.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Other financing activities changed N/A year-over-year to $183000.0, compared with a TTM value of $183000.0 through Dec 2024, up 357.75%, and an annual FY2024 reading of $183000.0, up 357.75% over the prior year.
  • Other financing activities was $183000.0 for Q1 2024 at Tandem Diabetes Care, up from -$71000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $183000.0 in Q1 2024 and bottomed at -$405000.0 in Q3 2022.
  • Average Other financing activities over 3 years is -$52500.0, with a median of $6000.0 recorded in 2022.
  • Peak annual rise in Other financing activities hit 82.47% in 2023, while the deepest fall reached 82.47% in 2023.
  • Year by year, Other financing activities stood at $83000.0 in 2022, then crashed by 185.54% to -$71000.0 in 2023, then skyrocketed by 357.75% to $183000.0 in 2024.
  • Business Quant data shows Other financing activities for TNDM at $183000.0 in Q1 2024, -$71000.0 in Q3 2023, and $83000.0 in Q4 2022.